Nuplazid (pimavanserin) has been reformulated into a once daily 34 mg capsule. It is the only FDA approved therapy proven to reduce delusions and hallucinations used for the treatment of Parkinson’s disease psychosis in elderly patients without impairing motor function.
It is now available as a once daily small capsule, as opposed to the previously available two 17mg capsules, taken with or without food.
As a reminder, no dosage adjustment of carbidopa/levodopa is needed when administered concomitantly with Nuplazid, but patients should be cautioned about the use of this drug with others known to increase QTC interval, which should be avoided.
Employee Spotlight (1)
Expert Insights (3)
Government Relations (21)
Policy Update (2)
Technology and Innovation (19)